Aclarion, Inc. announced they are extending their commercial agreement with the London Clinic in London, UK. The contract extension establishes a higher price point for Nociscan, engages The London Clinic to secure payer coverage decisions from leading private health insurers, and aligns Aclarion with The London Clinic in expanding access to referring physicians throughout the greater London market. The initial contract with The London Clinic was aimed at allowing The London Clinic physicians to evaluate the clinical value of Nociscan in treating their chronic low back pain patients.

After utilizing Nociscan in just 20 patients, the physicians saw enough value to support a contract extension aimed at increasing access to Nociscan for patients. Increased access is being pursued through outreach to referring physicians, increasing the reimbursement to Aclarion, and approaching the payer community to secure private insurance coverage for Nociscan. Chronic low back pain (cLBP) is a global healthcare problem with approximately 266 million people worldwide suffering from degenerative spine disease and low back pain.

Low back pain has been estimated to affect up to one third of the UK adult population each year.